



PINNACLE LIFESCIENCE

Subsidiary of  Aarti Drugs Ltd.



UNITED BY OUR GOAL TO BUILD A HEALTHIER WORLD



About Pinnacle Life Science

Pinnacle Life Science Pvt. Ltd, laid its foundation in 2015 and is a 100% subsidiary of Aarti Drugs Ltd (ADL) and forms part of \$ 1.5 billion conglomerate of the esteemed Aarti Group of Industries. A long commitment of 35 years towards healthcare through Aarti Drugs Ltd has enabled us to spread our wings in all directions. We are vertically integrated and specialize in bulk APIs, intermediates and finished formulations.

At Pinnacle, we are proud of our comprehensive portfolio with a strong presence in both acute and chronic ailment medication. Our annual production capacity is 3 billion tablets and 300 million capsules.

We are partnering with more than 250 clients and our global presence is in North America, Central America, Latin America (including Brazil, Mexico), Europe, UK, MENA region, French West Africa, East Africa, Australia, Central Asia and SouthEast Asia. Pinnacle has 2 state-of-the-art cGMP-compliant manufacturing facilities in India covering various therapeutic categories such as Anti-Diabetic, Anti-Cancer, Anti-Bacterials, Anti-Protozoal, Anti-Fungal, Anti-Allergic, Anti-Hypertensive, Anthelmintics, Gastrointestinal and Analgesics.

Our dedicated Oncology Facility is capable of manufacturing potent molecules upto OEB Level-5 and has been approved USFDA & audits for ANVISA & EU GMP have been triggered



Our Business Models Include



Out licensing of Dossiers & commercial supply



Co-development and product launch



Potent molecules development and supply



Technology transfer project



Contract Manufacturing facilities

Product List - Oncology
(US-FDA Approved Facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness
1	Abiraterone Acetate	250/500mg	Tablets	Available
2	Bicalutamide	50mg	Tablets	Available
3	Dasatinib	20/50/70/80/100/140mg	Tablets	Available
4	Imatinib	100/400mg	Tablets	Q3 2025
5	Lenalidomide	5/10/15/20/25mg	Capsules	Q4 2025
6	Palbociclib	75/100/125mg	Tablets	Q1 2026
7	Ruxolitinib	5/10/15/20/25mg	Tablets	Q1 2026
8	Ibrutinib	140/280/420/560mg	Tablets	Q1 2026
9	Axitinib	1/3/5mg	Tablets	Q2 2026
10	Enzalutamide	40/80mg	Tablets	Q2 2026
11	Everolimus ODT	2/3/5mg	Tablets	Q2 2026
12	Ibrutinib	140mg	Capsules	Q2 2026
13	Nilotinib	50/150/200mg	Capsules	Q2 2026
14	Palbociclib	75/100/125mg	Capsules	Q3 2026
15	Pazopanib	200/400mg	Tablets	Q3 2026
16	Regorafenib	40mg	Tablets	Q3 2026
17	Sunitinib	12.5/25/37.5/50mg	Capsules	Q3 2026
18	Lenvatinib	4/10mg	Capsules	Q3 2026
19	Apalutamide	60/240mg	Tablets	Q4 2026
20	Olaparib	100/150mg	Tablets	Q1 2027
21	Abemaciclib	50/100/150/200mg	Tablets	Under development
22	Afatinib	20/30/40mg	Tablets	Under development
23	Bosutinib	100/500mg	Tablets	Under development

Product List - Oncology (US-FDA Approved Facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness
24	Cabozantinib	20/40/60mg	Tablets	Under development
25	Pomalidomide	1/2/3/4mg	Capsules	Under development
26	Ribociclib	200mg	Tablets	Under development
27	Venetoclax	10/50/100mg	Tablets	Under development

Product List (UK-MHRA and EU-GMP Approved Facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness
1	Apixaban	2.5/5 mg	Tablets	Available
2	Celecoxib	100/200mg	Capsules	Available
3	Zolpidem	5/10mg	Tablets	Available
4	Tadalafil	2.5/5/10/20mg	Tablets	Available
5	Sitagliptin Hydrochloride	25/50/100mg	Tablets	Available
6	Clopidogrel	75mg	Tablets	Available
7	Dapagliflozin	5/10mg	Tablets	Available
8	Rivaroxaban	2.5/10/15/20mg	Tablets	Available
9	Sitagliptin Phosphate	25/50/100mg	Tablets	Available
10	Sitagliptin Phosphate + Metformin IR	50/500 mg 50/850 mg 50/1000 mg	Tablets	Available
11	Ticagrelor	60/90 mg	Tablets	Available
12	Vildagliptin	50 mg	Tablets	Available
13	Aripiprazole	10mg, 15 mg	Tablet	Available
14	Atorvastatin	10mg, 20mg, 40mg	Tablet	Available
15	Azithromycin	500mg	Tablet	Available
16	Carvedilol	25mg, 12.5mg, 6.25mg	Tablet	Available
17	Ciprofloxacin	500 mg	Tablet	Available
18	Dabigatran	75/110/150 mg	Capsules	Available
19	Desloratadine	5mg	Tablet	Available
20	Escitalopram	10mg, 20mg	Tablet	Available
21	Esomeperazole	20mg, 40mg	Capsule	Available
22	Furosemide	40mg	Tablet	Available
23	Ibuprofen	200mg, 400mg, 600mg	Tablet	Available

Product List (UK-MHRA and EU-GMP Approved Facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness
21	Esomperazole	20mg, 40mg	Capsule	Available
22	Furosemide	40mg	Tablet	Available
23	Ibuprofen	200mg, 400mg, 600mg	Tablet	Available
24	Losartan	50mg	Tablet	Available
25	Metformin IR	850mg	Tablet	Available
26	Metronidazole	500mg	Tablet	Available
27	Paracetamol	500mg	Tablet	Available
28	Pregabalin	75mg, 150mg	Capsule	Available
29	Quetiapine	25mg, 100mg	Tablet	Available
30	Sertralin	50mg	Tablet	Available
31	Tranexamic Acid	500mg	Tablet	Available
32	Vildagliptin	50mg	Tablet	Available
33	Famotidine	10/20/40 mg	Tablets	Q4 2025
34	Metformin XR	500/750/1000 mg	Tablets	Q4 2025
35	Sitagliptin Phosphate + Metformin XR	50 mg + 500 mg / 50 mg + 1000 mg / 100 mg + 1000 mg	Tablets	Q4 2025
36	Empaglifozin	10/25 mg	Tablets	Q4 2025
37	Levetiracetam	500 mg, 1000mg	Tablet	Q4 2025
38	Risperidone	1mg/ 3mg	Tablet	Q4 2025
39	Prochlorperazine	5/10mg	Tablets	Q1 2026
40	Perindopril + Amlodipine	5 mg + 5 mg / 5 mg + 10 mg/ 10 mg + 5 mg/ 10 mg + 10 mg	Tablets	Q1 2026
41	Linagliptin	5 mg	Tablets	Q1 2026

Product List (UK-MHRA and EU-GMP Approved Facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness
42	Dapagliflozin+ Metformin IR	5 mg + 850 mg / 5 mg + 1000 mg	Tablets	Q1 2026
43	Acamprosate	333 mg	Tablets	Q1 2026
44	Clobazam	10 mg	Tablets	Q1 2026
45	Clonazepam	0.5mg, 2mg	Tablets	Q1 2026
46	Apixaban	1mg/ 1ml	Oral Solution	Q2 2026
47	Sulfasalazine	500 mg	Tablets	Q2 2026
48	Dapagliflozin + Metformin XR	5 mg + 500 mg/ 10 mg + 500 mg/ 5 mg + 1000 mg/ 10 mg + 1000 mg	Tablets	Q2 2026
49	Emagliflozin +Linagliptin	10 mg + 5 mg/ 25 mg + 5 mg	Tablets	Q2 2026
50	Linagliptin + Metformin	2.5mg + 1000 mg	Tablets	Q2 2026
51	Mirabegron PR	25/50 mg	Tablets	Q2 2026
52	Azathioprine	50/75/100 mg	Tablets	Q2 2026
53	Budesonide	3 mg	Capsules	Q2 2026
54	Empagliflozin + Metformin	12.5mg + 1000 mg/ 12.5mg + 850 mg/ 5mg + 1000 mg/ 5mg + 850 mg/ 5mg + 500 mg	Tablets	Q3 2026
55	Leflunomide	10 mg	Tablets	Q2 2026




Oncology Facility



Approvals




Global Presence



Group of Companies



Get in touch: export.pinnacle@aartidrugs.com



Corporate office:

Pinnacle Life science, 3rd Floor, Mahendra Industrial Estate, Plot No. 109 D,
Road Number 29, Sion Cir, Mumbai - 400022, India. +(91) - (22) - 24019025